{"id":17196,"date":"2021-03-01T12:59:11","date_gmt":"2021-03-01T04:59:11","guid":{"rendered":"https:\/\/tbenews.com\/tbe\/?p=17196"},"modified":"2021-03-01T12:59:12","modified_gmt":"2021-03-01T04:59:12","slug":"snapshot-week-9-2021tbe-vaccination-in-transplant-patients","status":"publish","type":"post","link":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/","title":{"rendered":"Snapshot week 9\/2021<br>TBE vaccination in transplant patients"},"content":{"rendered":"<span class=\"cb-itemprop\" itemprop=\"reviewBody\">\n<p class=\"wp-block-paragraph\">In patients with allogeneic stem cell transplants (alloSCT) and autologous (autoSCT) recipients, the immune system is impaired and therefore, these patients have an increased risk to acquire severe infections.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A clinical study has been carried out in Sweden in patients after alloSCT (n=51) or autoSCT (n=53), and the aim to investigate the feasibility, side effects, and humoral response of four doses of TBE vaccine (FSME-Immun\u00ae, based on Neud\u00f6rfl strain) administered to these patients starting nine months post-transplant. The patients had a median age of 57 years, and in Sweden it is recommended to give four instead of three injections during the primary vaccination course in individuals aged at least 50 years. The control group was younger (median 39 years of age) and received three vaccine doses. For determination of IgG antibodies, an ELISA was used with a TBE antigen based on strain K23 and values of at least 12 U\/ml were considered seropositive.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The results showed that the vaccine induced a robust antibody level increase after auto- and alloSCT. 79% of all patients had antibody levels above the presumed protective limit after three injections compared to 100% in the healthy control group after three injections. The latter group had significantly higher GMTs in the last serum sample (142.8) compared to patients (37.8). In most patients, mild reactions, mostly local pain, and swelling were reported.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The optimal time for many vaccinations after alloSCT is yet not clearly defined and many vaccinations are recommended to start at six months after transplant. The durability of TBE vaccination in these patients is not known.<\/p>\n<\/span>","protected":false},"excerpt":{"rendered":"<p>In patients with allogeneic stem cell transplants (alloSCT) and autologous (autoSCT) recipients, the immune system is impaired and therefore, these patients have an increased risk to acquire severe infections. A clinical study has been carried out in Sweden in patients after alloSCT (n=51) or autoSCT (n=53), and the aim to investigate the feasibility, side effects, and humoral response of four doses of TBE vaccine (FSME-Immun\u00ae, based on Neud\u00f6rfl strain) administered to these patients starting nine months post-transplant. The patients had a median age of 57 years, and in Sweden it is recommended to give four instead of three injections during the primary vaccination course in individuals aged at least 50 years. The control group was younger (median 39 years of age) and received three vaccine doses. For determination of IgG antibodies, an ELISA was used with a TBE antigen based on strain K23 and values of at least 12 U\/ml were considered seropositive. The results showed that the vaccine induced a robust antibody level increase after auto- and alloSCT. 79% of all patients had antibody levels above the presumed protective limit after three injections compared to 100% in the healthy control group after three injections. The latter group had significantly higher GMTs in the last serum sample (142.8) compared to patients (37.8). In most patients, mild reactions, mostly local pain, and swelling were reported. The optimal time for many vaccinations after alloSCT is yet not clearly defined and many vaccinations are recommended to start at six months after transplant. The durability of TBE vaccination in these patients is not known.<\/p>\n","protected":false},"author":241,"featured_media":12864,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[18],"tags":[214,617,213,534],"coauthors":[172],"class_list":["post-17196","post","type-post","status-publish","format-standard","has-post-thumbnail","category-snapshot","tag-elisa","tag-fsme-immun","tag-sweden","tag-transplant-patients"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Snapshot week 9\/2021TBE vaccination in transplant patients - TBE Book<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snapshot week 9\/2021TBE vaccination in transplant patients - TBE Book\" \/>\n<meta property=\"og:description\" content=\"In patients with allogeneic stem cell transplants (alloSCT) and autologous (autoSCT) recipients, the immune system is impaired and therefore, these patients have an increased risk to acquire severe infections. A clinical study has been carried out in Sweden in patients after alloSCT (n=51) or autoSCT (n=53), and the aim to investigate the feasibility, side effects, and humoral response of four doses of TBE vaccine (FSME-Immun\u00ae, based on Neud\u00f6rfl strain) administered to these patients starting nine months post-transplant. The patients had a median age of 57 years, and in Sweden it is recommended to give four instead of three injections during the primary vaccination course in individuals aged at least 50 years. The control group was younger (median 39 years of age) and received three vaccine doses. For determination of IgG antibodies, an ELISA was used with a TBE antigen based on strain K23 and values of at least 12 U\/ml were considered seropositive. The results showed that the vaccine induced a robust antibody level increase after auto- and alloSCT. 79% of all patients had antibody levels above the presumed protective limit after three injections compared to 100% in the healthy control group after three injections. The latter group had significantly higher GMTs in the last serum sample (142.8) compared to patients (37.8). In most patients, mild reactions, mostly local pain, and swelling were reported. The optimal time for many vaccinations after alloSCT is yet not clearly defined and many vaccinations are recommended to start at six months after transplant. The durability of TBE vaccination in these patients is not known.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"TBE Book\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-01T04:59:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-01T04:59:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Michael Broeker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Michael Broeker\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\\\/\"},\"author\":{\"name\":\"Michael Broeker\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/03f04d14182a6183d413e7ac1042c4bb\"},\"headline\":\"Snapshot week 9\\\/2021 TBE vaccination in transplant patients\",\"datePublished\":\"2021-03-01T04:59:11+00:00\",\"dateModified\":\"2021-03-01T04:59:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\\\/\"},\"wordCount\":261,\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"keywords\":[\"ELISA\",\"FSME Immun\",\"Sweden\",\"transplant patients\"],\"articleSection\":[\"Snapshot\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\\\/\",\"name\":\"Snapshot week 9\\\/2021 TBE vaccination in transplant patients - TBE Book\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"datePublished\":\"2021-03-01T04:59:11+00:00\",\"dateModified\":\"2021-03-01T04:59:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Snapshots.jpg\",\"width\":1180,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Snapshot week 9\\\/2021TBE vaccination in transplant patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"name\":\"The TBE Book\",\"description\":\"Tick-borne Encephalitis (TBE)\",\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\",\"name\":\"Global Health Press\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"width\":1000,\"height\":715,\"caption\":\"Global Health Press\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/03f04d14182a6183d413e7ac1042c4bb\",\"name\":\"Michael Broeker\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/99401f1a598a13b049574558929ae14b6bbe2ea3f66708df828cfcd8ecf5589d?s=96&d=mm&r=g94a27e445c4371097d1dea87a2f962e9\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/99401f1a598a13b049574558929ae14b6bbe2ea3f66708df828cfcd8ecf5589d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/99401f1a598a13b049574558929ae14b6bbe2ea3f66708df828cfcd8ecf5589d?s=96&d=mm&r=g\",\"caption\":\"Michael Broeker\"},\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/author\\\/michael-broeker\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Snapshot week 9\/2021TBE vaccination in transplant patients - TBE Book","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/","og_locale":"en_US","og_type":"article","og_title":"Snapshot week 9\/2021TBE vaccination in transplant patients - TBE Book","og_description":"In patients with allogeneic stem cell transplants (alloSCT) and autologous (autoSCT) recipients, the immune system is impaired and therefore, these patients have an increased risk to acquire severe infections. A clinical study has been carried out in Sweden in patients after alloSCT (n=51) or autoSCT (n=53), and the aim to investigate the feasibility, side effects, and humoral response of four doses of TBE vaccine (FSME-Immun\u00ae, based on Neud\u00f6rfl strain) administered to these patients starting nine months post-transplant. The patients had a median age of 57 years, and in Sweden it is recommended to give four instead of three injections during the primary vaccination course in individuals aged at least 50 years. The control group was younger (median 39 years of age) and received three vaccine doses. For determination of IgG antibodies, an ELISA was used with a TBE antigen based on strain K23 and values of at least 12 U\/ml were considered seropositive. The results showed that the vaccine induced a robust antibody level increase after auto- and alloSCT. 79% of all patients had antibody levels above the presumed protective limit after three injections compared to 100% in the healthy control group after three injections. The latter group had significantly higher GMTs in the last serum sample (142.8) compared to patients (37.8). In most patients, mild reactions, mostly local pain, and swelling were reported. The optimal time for many vaccinations after alloSCT is yet not clearly defined and many vaccinations are recommended to start at six months after transplant. The durability of TBE vaccination in these patients is not known.","og_url":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/","og_site_name":"TBE Book","article_published_time":"2021-03-01T04:59:11+00:00","article_modified_time":"2021-03-01T04:59:12+00:00","og_image":[{"width":1180,"height":250,"url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","type":"image\/jpeg"}],"author":"Michael Broeker","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Michael Broeker","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/#article","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/"},"author":{"name":"Michael Broeker","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/03f04d14182a6183d413e7ac1042c4bb"},"headline":"Snapshot week 9\/2021 TBE vaccination in transplant patients","datePublished":"2021-03-01T04:59:11+00:00","dateModified":"2021-03-01T04:59:12+00:00","mainEntityOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/"},"wordCount":261,"publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","keywords":["ELISA","FSME Immun","Sweden","transplant patients"],"articleSection":["Snapshot"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/","url":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/","name":"Snapshot week 9\/2021 TBE vaccination in transplant patients - TBE Book","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/#primaryimage"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","datePublished":"2021-03-01T04:59:11+00:00","dateModified":"2021-03-01T04:59:12+00:00","breadcrumb":{"@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/#primaryimage","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Snapshots.jpg","width":1180,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/tbenews.com\/tbe\/snapshot-week-9-2021tbe-vaccination-in-transplant-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tbenews.com\/tbe\/"},{"@type":"ListItem","position":2,"name":"Snapshot week 9\/2021TBE vaccination in transplant patients"}]},{"@type":"WebSite","@id":"https:\/\/tbenews.com\/tbe\/#website","url":"https:\/\/tbenews.com\/tbe\/","name":"The TBE Book","description":"Tick-borne Encephalitis (TBE)","publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tbenews.com\/tbe\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tbenews.com\/tbe\/#organization","name":"Global Health Press","url":"https:\/\/tbenews.com\/tbe\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","width":1000,"height":715,"caption":"Global Health Press"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/03f04d14182a6183d413e7ac1042c4bb","name":"Michael Broeker","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/99401f1a598a13b049574558929ae14b6bbe2ea3f66708df828cfcd8ecf5589d?s=96&d=mm&r=g94a27e445c4371097d1dea87a2f962e9","url":"https:\/\/secure.gravatar.com\/avatar\/99401f1a598a13b049574558929ae14b6bbe2ea3f66708df828cfcd8ecf5589d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/99401f1a598a13b049574558929ae14b6bbe2ea3f66708df828cfcd8ecf5589d?s=96&d=mm&r=g","caption":"Michael Broeker"},"url":"https:\/\/tbenews.com\/tbe\/author\/michael-broeker\/"}]}},"_links":{"self":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/17196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/users\/241"}],"replies":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/comments?post=17196"}],"version-history":[{"count":1,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/17196\/revisions"}],"predecessor-version":[{"id":17197,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/17196\/revisions\/17197"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media\/12864"}],"wp:attachment":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media?parent=17196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/categories?post=17196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/tags?post=17196"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/coauthors?post=17196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}